Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Oral corticosteroid use during pregnancy poses no risk of congenital heart defects

26 Nov 2019

Exposure to oral corticosteroids during pregnancy bears no harm to the offspring in terms of the risk of congenital heart defects (CHDs), a study reports.

Using data from a register-based nationwide prevalence study including all live singleton births in Denmark, researchers looked at 1,194,687 mother-and-child pairs to assess the risk of offspring CHDs in relation to the mothers’ use of oral corticosteroids in early pregnancy.

A total of 2,032 individuals (0.17 percent) had a mother who filled a prescription for oral corticosteroids during the 0–8-week period after conception, whereas 1,142,091 (96 percent) had a mother who never used the drugs.

CHDs were documented in 11,094 individuals, yielding a prevalence rate of 93 per 10,000. The crude prevalence was higher in individuals whose mothers filled a prescription for oral corticosteroids in weeks 0–8 after conception than in those whose mothers were never exposed to the drug (32 vs 10,534; prevalence, 157 vs 92 per 10,000; prevalence ratio [PR], 1.72, 95 percent confidence interval [CI] 1.21–2.44).

However, the PR was attenuated following adjustments for maternal age, birth order, calendar year and other covariates associated with corticosteroid exposure and CHD (1.29, 95 percent CI, 0.90–1.84; p=0.16). Propensity score-matched analysis yielded similar results (PR, 1.38, 95 percent CI, 0.95–2.02).

In light of the findings, the researchers pointed out that there is no reason to refrain from corticosteroid treatment during early pregnancy, especially when there is a clear and pertinent indication.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.